Please note that this is a general product information according to US approvals, for specific regulatory information concerning your market please contact Regulatory department email: Regulatory.AffairsMER@zoetis.com
EXCEDE is indicated for the treatment of lower respiratory tract infections in horses caused by susceptible strains of Streptococcus equi subspecies zooepidemicus (S. zooepidemicus). EXCEDE contains ceftiofur in a crystalline form, called Ceftiofur Crystalline Free Acid, or CCFA. The final product is a ready-to-use sterile suspension of CCFA in oil.
EXCEDE is the first and only licensed antibiotic for horses that offers a full course of therapy in just 2 doses. By reducing the administration requirements from 10 daily doses of a comparative antibiotic to a 2-dose regimen, EXCEDE makes the treatment process less stressful for the horse and more convenient for the veterinarian, caretaker and horse owner.
The use of EXCEDE provides veterinarians peace of mind, knowing they have selected a product that has been demonstrated to be both safe and effective in horses. EXCEDE is available through veterinary prescription only
One-of-a-kind
As the first and only sustained-release licensed antibiotic for horses, EXCEDE offers a full-course of therapy in just 2 doses for the treatment of lower respiratory tract infections caused by susceptible strains of S. zooepidemicus, the most common bacterial pathogen isolated from equine respiratory infections1-5
Fewer doses
By providing 10 days of therapy in just 2 doses administered 4 days apart, versus 10 daily doses of a comparative antibiotic, veterinarians can optimize compliance. Fewer administrations means less potential for missed doses
Benefits beyond the bottle
EXCEDE makes the treatment process less stressful for the horse, horse owner and caretaker. The sustained-release nature of the product means less systemic exposure to the antibiotic with comparable efficacy
Exceptional value
EXCEDE provides a full course of therapy with fewer administrations, making it an affordable option
When injected intramuscularly, EXCEDE is continuously released into the bloodstream and is rapidly metabolized into its active form, thereby achieving a plasma level above the minimum inhibitory concentration (MIC) for S. zooepidemicus of at least 4 days for the first injection and up to 10 days after 2 injections, administered 96 hours apart. This results in long-acting and safe therapeutic levels. Dosage is 3 mg/lb (6.6mg/kg) with a maximum of 20mL per injection site.
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
